# Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy

> **NCT03208231** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 61 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC01
- **DRUG:** Combination Antiretroviral Therapy (cART)

## Key facts

- **NCT ID:** NCT03208231
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-06
- **Primary completion:** 2020-06-16
- **Final completion:** 2021-02-11
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208231, "Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in Infants With HIV Receiving Combination Antiretroviral Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03208231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*